[go: up one dir, main page]

EE200300355A - Neublastiini polümeerkonjugaadid ja meetodid nende kasutamiseks - Google Patents

Neublastiini polümeerkonjugaadid ja meetodid nende kasutamiseks

Info

Publication number
EE200300355A
EE200300355A EEP200300355A EEP200300355A EE200300355A EE 200300355 A EE200300355 A EE 200300355A EE P200300355 A EEP200300355 A EE P200300355A EE P200300355 A EEP200300355 A EE P200300355A EE 200300355 A EE200300355 A EE 200300355A
Authority
EE
Estonia
Prior art keywords
neublastin
methods
polymer conjugates
conjugates
polymer
Prior art date
Application number
EEP200300355A
Other languages
English (en)
Inventor
W. Y. Sah Dinah
Blake Pepinsky R.
Ann Borjack-Sjodin Paula
S. Miller Stephan
Rossomando Anthony
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of EE200300355A publication Critical patent/EE200300355A/et
Publication of EE05537B1 publication Critical patent/EE05537B1/et

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/4756Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
EEP200300355A 2001-02-01 2002-01-25 Neublastiini polmeerkonjugaadid ja meetodid nende kasutamiseks EE05537B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26607101P 2001-02-01 2001-02-01
PCT/US2002/002319 WO2002060929A2 (en) 2001-02-01 2002-01-25 Polymer conjugates of neublastin and methods of using same

Publications (2)

Publication Number Publication Date
EE200300355A true EE200300355A (et) 2003-10-15
EE05537B1 EE05537B1 (et) 2012-04-16

Family

ID=23013042

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300355A EE05537B1 (et) 2001-02-01 2002-01-25 Neublastiini polmeerkonjugaadid ja meetodid nende kasutamiseks

Country Status (36)

Country Link
EP (2) EP1862475A1 (et)
JP (2) JP4259868B2 (et)
KR (2) KR100872807B1 (et)
CN (1) CN1500095B (et)
AR (1) AR035077A1 (et)
AT (1) ATE365748T1 (et)
AU (1) AU2002247037B2 (et)
BG (1) BG66393B1 (et)
BR (1) BR0206852A (et)
CA (1) CA2436407C (et)
CY (1) CY1106886T1 (et)
CZ (1) CZ20032080A3 (et)
DE (1) DE60220879T2 (et)
DK (1) DK1355936T3 (et)
EA (1) EA009771B1 (et)
EE (1) EE05537B1 (et)
ES (1) ES2289091T3 (et)
GE (1) GEP20063916B (et)
HK (1) HK1057759A1 (et)
HU (1) HU228973B1 (et)
IL (2) IL156941A0 (et)
IS (1) IS2867B (et)
MX (1) MXPA03006805A (et)
MY (1) MY143685A (et)
NO (1) NO332150B1 (et)
NZ (1) NZ527863A (et)
PL (1) PL211162B1 (et)
PT (1) PT1355936E (et)
RS (1) RS50857B (et)
SG (1) SG149685A1 (et)
SI (1) SI1355936T1 (et)
SK (1) SK288123B6 (et)
TR (1) TR200301208T2 (et)
UA (2) UA82983C2 (et)
WO (1) WO2002060929A2 (et)
ZA (1) ZA200305733B (et)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
AU2002247037B2 (en) * 2001-02-01 2007-08-16 Biogen Ma Inc. Polymer conjugates of neublastin and methods of using same
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
EP1395279B1 (en) * 2001-03-28 2011-10-05 Biogen Idec MA Inc. Use of neublastin polypeptides for treating neuropathic pain
DK1476181T3 (en) * 2002-01-18 2016-05-23 Biogen Ma Inc POLYALKYLENE POLYMER COMPOUNDS AND USE THEREOF
DK1594436T3 (da) * 2003-01-31 2010-12-13 Biogen Idec Inc Polymerkonjugater af muteret neublastin
DE602004021648D1 (de) 2003-04-18 2009-07-30 Biogen Idec Inc Polymerkonjugiertes glycosiliertes Neublastin
ATE423134T1 (de) 2003-06-10 2009-03-15 Nsgene As Verbesserte sezernierung von neublastin
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
PL1786454T3 (pl) 2004-08-19 2010-12-31 Biogen Ma Inc Odmiany neublastyny
CA2577690C (en) * 2004-08-19 2013-08-06 Biogen Idec Ma Inc. Refolding transforming growth factor beta family proteins
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
US20100056440A1 (en) * 2006-03-01 2010-03-04 Biogen Idec Ma Inc. Compositions and methods for administering gdnf ligand family proteins
JP2010503630A (ja) 2006-09-15 2010-02-04 クレアビリス・セラピューティクス・エスピーエー HMGB1のBox−AおよびHMGB1のBox−A変異体のポリマー複合体
TWI445544B (zh) * 2007-05-01 2014-07-21 Biogen Idec Inc 增進血管形成之組合物及方法
US20140301977A1 (en) * 2011-11-02 2014-10-09 Genentech, Inc. Overload and elute chromatography
RU2488635C1 (ru) * 2012-03-22 2013-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития Способ получения рекомбинантного антиангиогенного полипептида

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472178B1 (en) * 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
EP1137774A2 (en) * 1998-12-09 2001-10-04 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor
AU2002247037B2 (en) * 2001-02-01 2007-08-16 Biogen Ma Inc. Polymer conjugates of neublastin and methods of using same

Also Published As

Publication number Publication date
YU61003A (sh) 2006-05-25
DE60220879D1 (de) 2007-08-09
BR0206852A (pt) 2005-05-03
AR035077A1 (es) 2004-04-14
AU2002247037B2 (en) 2007-08-16
GEP20063916B (en) 2006-09-11
HU228973B1 (en) 2013-07-29
SK9712003A3 (en) 2004-01-08
EE05537B1 (et) 2012-04-16
NZ527863A (en) 2006-09-29
KR100960063B1 (ko) 2010-05-31
PL372101A1 (en) 2005-07-11
SG149685A1 (en) 2009-02-27
WO2002060929A3 (en) 2003-03-06
ATE365748T1 (de) 2007-07-15
WO2002060929A2 (en) 2002-08-08
NO20033441D0 (no) 2003-08-01
KR20080098662A (ko) 2008-11-11
UA82983C2 (ru) 2008-06-10
EP1355936A2 (en) 2003-10-29
CN1500095B (zh) 2010-06-16
EA009771B1 (ru) 2008-04-28
IS2867B (is) 2014-02-15
EP1862475A1 (en) 2007-12-05
JP2009039135A (ja) 2009-02-26
UA100967C2 (ru) 2013-02-25
TR200301208T2 (tr) 2005-05-23
MY143685A (en) 2011-06-30
HK1057759A1 (en) 2004-04-16
SK288123B6 (sk) 2013-09-03
SI1355936T1 (sl) 2007-12-31
NO20033441L (no) 2003-10-01
KR100872807B1 (ko) 2008-12-09
PT1355936E (pt) 2007-09-28
JP4259868B2 (ja) 2009-04-30
BG108111A (bg) 2004-12-30
RS50857B (sr) 2010-08-31
EP1355936B1 (en) 2007-06-27
CZ20032080A3 (cs) 2003-10-15
IS6879A (is) 2003-07-17
CN1500095A (zh) 2004-05-26
DK1355936T3 (da) 2007-10-29
CA2436407A1 (en) 2002-08-08
CA2436407C (en) 2011-08-30
JP2005503763A (ja) 2005-02-10
PL211162B1 (pl) 2012-04-30
MXPA03006805A (es) 2003-11-13
IL156941A0 (en) 2004-02-08
HUP0500637A3 (en) 2010-01-28
NO332150B1 (no) 2012-07-09
ZA200305733B (en) 2005-02-23
DE60220879T2 (de) 2008-03-06
EA200300852A1 (ru) 2004-06-24
CY1106886T1 (el) 2012-09-26
IL156941A (en) 2008-11-03
ES2289091T3 (es) 2008-02-01
BG66393B1 (bg) 2013-11-29
JP4423338B2 (ja) 2010-03-03
KR20030074766A (ko) 2003-09-19
HUP0500637A2 (hu) 2005-09-28

Similar Documents

Publication Publication Date Title
CY2013032I1 (el) Συζυγη της εξενδινης-4 και η φαρμακευτικη τους χρηση
EE200300145A (et) Asa- ja polüasanaftalenüülkarboksamiidid ja farmatseutiline kompositsioon
NO20025580D0 (no) Medisinsk anordning
NO20040778L (no) Superabsorberende polymer
NO20020235D0 (no) Medisinsk anordning
NO20025578L (no) Medisinsk innretning
ATE355271T1 (de) Pharmazeutische zusammensetzung
EE200300355A (et) Neublastiini polümeerkonjugaadid ja meetodid nende kasutamiseks
EE200300311A (et) Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
EE200200626A (et) Antraniilamiidid ja nende kasutamine ravimitena
EE200300193A (et) Asendatud bensimidasoolid, nende kasutamine ja ravim
FI20011671A0 (fi) Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö
MA26998A1 (fr) Conjugues peg de hgt-nk4
DE60137941D1 (de) Polymerzusammensetzung
FI20000818A0 (fi) Dermatologinen käyttö ja valmiste
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
DE60129238D1 (de) Pharmazeutische zusammensetzung
DE60217539D1 (de) Leichtathletikschuh
EE200300480A (et) Pregabaliini-laktoosi konjugaadid
DE10291905D2 (de) Pharmazeutische Zusammensetzung
DE60008489D1 (de) Lösbarer Endanschlag
FI20012016L (fi) Eettereitä hajottavia bakteereita ja niiden käyttö
DE10107261B4 (de) Pharmazeutische Zusammensetzung
EP1413314A4 (en) MEDICAL COMPOSITIONS
FR2816398B3 (fr) Fronde perfectionnee

Legal Events

Date Code Title Description
HC1A Change of owner name
MM4A Lapsed by not paying the annual fees

Effective date: 20160125